Miana Leonardo A, Manuel Valdano, Turquetto Aida Luísa, Issa Hugo Neder, Guerreiro Gustavo Pampolha, Caneo Luiz Fernando, Jatene Fábio Biscegli, Jatene Marcelo Biscegli
Division of Cardiovascular Surgery, Heart Institute (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Cardio-Thoracic Center, Clínica Girassol, Luanda, Angola.
World J Pediatr Congenit Heart Surg. 2020 Jan;11(1):22-28. doi: 10.1177/2150135119884916.
Atrioventricular valve (AVV) regurgitation in patients with single ventricle (SV) physiology severely impacts prognosis; the appropriate timing for surgical treatment is unknown. We sought to study the results of surgical treatment of AVV regurgitation in SV patients and evaluate risk factors for mortality.
Medical records of 81 consecutive patients with moderate or severe AAV regurgitation who were submitted to AVV repair or replacement during any stage of univentricular palliation between January 2013 and May 2017 were examined. We studied demographic data and perioperative factors looking for predictors that might have influenced the results. Binary logistic regression was used to assess the impact on postoperative ventricular dysfunction and mortality.
Median age and weight were seven months (interquartile range [IQR]: 3-24) and 5.2 kg (IQR: 3.7-11.2), respectively. Seventy (86.4%) patients underwent AVV repair, and 11 (13.6%) patients underwent AVV replacement. There was an association between AVV repair effectiveness and timing of intervention ( = .004). Atrioventricular valve intervention at the time of initial surgical palliation was associated with more ineffective repairs ( = .001), while AVV replacement was more common between Glenn and Fontan procedures ( = .004). Overall 30-day mortality was 30.5% (25 patients). In-hospital mortality was 49.4%, and it was higher when AVV repair was performed concomitant with initial (stage 1) palliation (64.1% vs 35.7%; = .01) and when an effective repair was not achieved (75% vs 41%; = .008). Multivariable analysis identified timing concomitant with stage 1 palliation as an independent risk factor for mortality ( = .01); meanwhile, an effective repair was a protective factor against in-hospital mortality ( = .05).
Univentricular physiology with AVV regurgitation is a high-risk group of patients. Surgery for AVV regurgitation at stage 1 palliation was associated with less effective repair and higher mortality in this initial experience. On the other hand, effective repair determined better outcomes, highlighting the importance of experience and the learning curve in the management of such patients.
单心室(SV)生理状态患者的房室瓣(AVV)反流严重影响预后;手术治疗的合适时机尚不清楚。我们试图研究SV患者AVV反流的手术治疗结果,并评估死亡的危险因素。
检查了2013年1月至2017年5月期间在单心室姑息治疗的任何阶段接受AVV修复或置换的81例连续中度或重度AAV反流患者的病历。我们研究了人口统计学数据和围手术期因素,以寻找可能影响结果的预测因素。采用二元逻辑回归评估对术后心室功能障碍和死亡率的影响。
中位年龄和体重分别为7个月(四分位间距[IQR]:3 - 24)和5.2 kg(IQR:3.7 - 11.2)。70例(86.4%)患者接受了AVV修复,11例(13.6%)患者接受了AVV置换。AVV修复效果与干预时机之间存在关联(P = .004)。初次手术姑息治疗时进行房室瓣干预与修复效果较差相关(P = .001),而AVV置换在格林分流术和Fontan手术之间更为常见(P = .004)。总体30天死亡率为30.5%(25例患者)。住院死亡率为49.4%,当AVV修复与初次(1期)姑息治疗同时进行时更高(64.1%对35.7%;P = .01),以及当未实现有效修复时更高(75%对41%;P = .008)。多变量分析确定与1期姑息治疗同时进行的时机是死亡的独立危险因素(P = .01);同时,有效修复是预防住院死亡的保护因素(P = .05)。
伴有AVV反流的单心室生理状态患者是高危患者群体。在本次初步经验中,1期姑息治疗时进行AVV反流手术与修复效果较差和死亡率较高相关。另一方面,有效修复决定了更好的结果,突出了经验和学习曲线在这类患者管理中的重要性。